---
title: "Graph AI’s $13.3M Series A: Insight Bets on AI Pharmacovigilance"
description: "Insight led $13.3M Series A for Graph Safety on Sep 10, 2026, with Bessemer returning — company claims live PV deployments cut case turnaround >90% and opex up to 66% for pharma safety teams."
date: 2026-09-11T00:00:00.000Z
source: https://venturecapitaltracker.com/2026-graph-ai-13-3m-series-a-insight-bessemer-patient-safety
---

# Graph AI’s $13.3M Series A: Insight Bets on AI Pharmacovigilance

> Insight led $13.3M Series A for Graph Safety on Sep 10, 2026, with Bessemer returning — company claims live PV deployments cut case turnaround >90% and opex up to 66% for pharma safety teams.

**[Graph AI](/startup/graph-ai)** closed a **$13.3 million** Series A on **September 10, 2026**, led by [Insight Partners](/fund/insight-partners), with [Bessemer Venture Partners](/fund/bessemer-venture-partners) returning after leading the October 2025 seed (company PR). Valuation and ARR were **not disclosed**.

Pharmacovigilance has scaled by hiring people around legacy case systems. Graph’s bet is that regulated AI with audit trails can eat the **services layer** — and Insight is underwriting measured turnaround cuts, not a chatbot demo.

## Key facts

| Field | Detail |
| --- | --- |
| Company | [Graph AI](/startup/graph-ai) ([graphsafety.ai](https://graphsafety.ai)), Pleasanton, CA |
| Round | **$13.3M** Series A |
| Lead | Insight Partners (Richard Matus quoted) |
| Returning | Bessemer (seed lead, Oct 2025) |
| Founded | 2024 — CEO Raghav Parvataraju |
| Modules | /intake, /nucleus live; /report launching Sep 2026; /signal in design partnerships |
| Claimed outcomes | Case TAT **>3h → <10 min**; opex **down up to 66%** (company) |

## Who uses the product — and for what job

**Users:** pharmaceutical and biotech patient-safety / PV teams that currently stitch intake channels, case databases, and aggregate reports with manual handoffs.

**Job:** capture adverse events across channels → automate case processing with deterministic controls and audit trails → keep humans on judgment and signal analysis. The company positions the stack against FDA AI credibility guidance, the EU AI Act, and CIOMS WG XIV expectations — treat that as **design intent**, not a regulatory approval claim.

Named customer logos were **not** listed in the Series A release; the company says it has onboarded pharma/biotech customers in North America and other markets.

## Why now

- Case volumes rise while PV orgs remain **people + process** heavy.
- Generics “AI for safety” without traceability fail inspection culture; Graph’s pitch is AI **plus** deterministic validation.
- Seed-to-Series A in under a year with two shipped modules is the product proof Insight is buying.

## Why Insight + Bessemer — portfolio fit

| Investor | Likely fit |
| --- | --- |
| [Insight](/fund/insight-partners) | Scale-up software that replaces services spend inside enterprises — classic Insight pattern |
| [Bessemer](/fund/bessemer-venture-partners) | Seed conviction recycle; healthcare AI portfolio adjacency (Abridge et al. in firm narrative) |

Strategic rationale for raising now: US/Europe expansion and shipping /report + /signal while the services incumbents still sell integration labor.

## Competitive map

| Approach | Tradeoff |
| --- | --- |
| Legacy PV vendors + BPOs | Installed base; slow / expensive ops |
| Point AI copilots on old databases | Fast demos; weak audit story |
| Graph Safety AI-native OS | End-to-end modules; must win regulated validation cycles |

## What remains undisclosed

Valuation, ARR, customer count, and whether the 90%/66% figures are median or best-case sites. Those are the numbers that turn a strong PR claim into underwritable SaaS math.

## Sources

- [PR Newswire](https://www.prnewswire.com/news-releases/graph-ai-raises-13-3m-series-a-to-scale-the-first-ai-native-operating-system-for-patient-safety-302874459.html)

**By:** [Venture Capital Tracker](https://venturecapitaltracker.com/editorial-policy)

**Editorial note:** AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.